CN110652525A - 甘露糖醛二酸的组合物在治疗炎症中的应用 - Google Patents

甘露糖醛二酸的组合物在治疗炎症中的应用 Download PDF

Info

Publication number
CN110652525A
CN110652525A CN201810721276.7A CN201810721276A CN110652525A CN 110652525 A CN110652525 A CN 110652525A CN 201810721276 A CN201810721276 A CN 201810721276A CN 110652525 A CN110652525 A CN 110652525A
Authority
CN
China
Prior art keywords
composition
mannuronic acid
sum
weight
total weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810721276.7A
Other languages
English (en)
Chinese (zh)
Inventor
耿美玉
辛现良
张真庆
丁健
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Shanghai Green Valley Pharmaceutical Co Ltd
Original Assignee
Shanghai Institute of Materia Medica of CAS
Shanghai Green Valley Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS, Shanghai Green Valley Pharmaceutical Co Ltd filed Critical Shanghai Institute of Materia Medica of CAS
Priority to CN201810721276.7A priority Critical patent/CN110652525A/zh
Priority to JP2020572815A priority patent/JP2021529195A/ja
Priority to PCT/CN2019/093656 priority patent/WO2020001611A1/zh
Priority to AU2019296419A priority patent/AU2019296419A1/en
Priority to US17/256,854 priority patent/US11406659B2/en
Priority to KR1020217001707A priority patent/KR20210040041A/ko
Priority to EP19825915.2A priority patent/EP3815693A4/en
Publication of CN110652525A publication Critical patent/CN110652525A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201810721276.7A 2018-06-29 2018-06-29 甘露糖醛二酸的组合物在治疗炎症中的应用 Pending CN110652525A (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN201810721276.7A CN110652525A (zh) 2018-06-29 2018-06-29 甘露糖醛二酸的组合物在治疗炎症中的应用
JP2020572815A JP2021529195A (ja) 2018-06-29 2019-06-28 炎症の治療におけるマンヌロン二酸組成物の使用
PCT/CN2019/093656 WO2020001611A1 (zh) 2018-06-29 2019-06-28 甘露糖醛二酸的组合物在治疗炎症中的应用
AU2019296419A AU2019296419A1 (en) 2018-06-29 2019-06-28 Use of mannuronic dicarboxylic acid composition in treatment of inflammation
US17/256,854 US11406659B2 (en) 2018-06-29 2019-06-28 Use of mannuronic diacid composition in treatment of inflammation
KR1020217001707A KR20210040041A (ko) 2018-06-29 2019-06-28 염증 치료에서의 만누론 이산 조성물의 용도
EP19825915.2A EP3815693A4 (en) 2018-06-29 2019-06-28 USE OF A DICARBOXYLIC MANNURONIC ACID COMPOSITION IN THE TREATMENT OF INFLAMMATION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810721276.7A CN110652525A (zh) 2018-06-29 2018-06-29 甘露糖醛二酸的组合物在治疗炎症中的应用

Publications (1)

Publication Number Publication Date
CN110652525A true CN110652525A (zh) 2020-01-07

Family

ID=68985392

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810721276.7A Pending CN110652525A (zh) 2018-06-29 2018-06-29 甘露糖醛二酸的组合物在治疗炎症中的应用

Country Status (7)

Country Link
US (1) US11406659B2 (https=)
EP (1) EP3815693A4 (https=)
JP (1) JP2021529195A (https=)
KR (1) KR20210040041A (https=)
CN (1) CN110652525A (https=)
AU (1) AU2019296419A1 (https=)
WO (1) WO2020001611A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025245773A1 (zh) * 2024-05-30 2025-12-04 海糖（江苏）生物医药科技有限公司 一种褐藻寡糖衍生物及其制备方法和用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112336742A (zh) * 2019-08-06 2021-02-09 上海绿谷制药有限公司 甘露糖醛酸寡糖治疗Th1主导相关疾病的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106344594A (zh) * 2015-07-17 2017-01-25 上海绿谷制药有限公司 褐藻胶寡糖及其衍生物在治疗炎症中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1562050A (zh) * 2004-03-24 2005-01-12 中国海洋大学 褐藻酸寡糖在抗痴呆、抗糖尿病中的应用
WO2007069468A1 (ja) * 2005-12-14 2007-06-21 Nagasaki University サイトカイン分泌促進剤
JP2016108474A (ja) * 2014-12-08 2016-06-20 栄治 松村 オリゴ糖の製造方法およびオリゴ糖
CN106344592A (zh) 2015-07-17 2017-01-25 上海绿谷制药有限公司 还原端1位为羧基的甘露糖醛酸寡糖及其衍生物在治疗帕金森氏症中的应用
CN106344595B (zh) 2015-07-17 2020-06-19 上海绿谷制药有限公司 褐藻胶寡糖及其衍生物在制备治疗疼痛药物中的应用
DE102016113018A1 (de) * 2016-07-14 2018-01-18 Abbas Mirshafiey Pharmazeutische Verwendung von beta-D-Mannuronsäure
PL3498722T3 (pl) * 2016-08-15 2021-09-20 Shanghai Green Valley Pharmaceutical Co., Ltd. Sposób przygotowania oligomerycznego dikwasu mannuronowego
JP6977059B2 (ja) * 2016-12-30 2021-12-08 シャンハイ、グリーン、バレー、ファーマスーティカル、カンパニー、リミテッドShanghai Green Valley Pharmaceutical Co., Ltd. マンヌロン二酸の組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106344594A (zh) * 2015-07-17 2017-01-25 上海绿谷制药有限公司 褐藻胶寡糖及其衍生物在治疗炎症中的应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025245773A1 (zh) * 2024-05-30 2025-12-04 海糖（江苏）生物医药科技有限公司 一种褐藻寡糖衍生物及其制备方法和用途

Also Published As

Publication number Publication date
EP3815693A1 (en) 2021-05-05
EP3815693A4 (en) 2022-04-20
US11406659B2 (en) 2022-08-09
WO2020001611A1 (zh) 2020-01-02
KR20210040041A (ko) 2021-04-12
AU2019296419A1 (en) 2021-01-28
US20210275570A1 (en) 2021-09-09
JP2021529195A (ja) 2021-10-28

Similar Documents

Publication Publication Date Title
JP6977059B2 (ja) マンヌロン二酸の組成物
CN110652525A (zh) 甘露糖醛二酸的组合物在治疗炎症中的应用
CN110652516A (zh) 甘露糖醛二酸的组合物在治疗帕金森氏症中的应用
US11406652B2 (en) Use of mannuronic diacid composition in treatment of diabetes
HK40014915A (en) Use of a composition of oligomeric mannuronic diacid for treating inflammation
CN110652524A (zh) 甘露糖醛二酸的组合物在治疗疼痛中的应用
CN110652523A (zh) 甘露糖醛二酸的组合物在治疗血管性痴呆症中的应用
HK40014917A (en) Use of a composition of oligomeric mannuronic diacid for treating parkinson's disease
HK40016250A (en) Use of a composition of mannuronic diacids in the treatment of diabetes
HK40016251A (en) Use of a composition of mannuronic diacids in the treatment of pain
US20220362271A1 (en) Use of mannuronic acid oligosaccharides or composition comprising same in treatment of th1-dominance related diseases
HK40014916A (en) Use of a composition of oligomeric mannuronic diacid for treating vascular dementia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40014915

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20200107

RJ01 Rejection of invention patent application after publication